By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid today announced a partnership with Novartis to commercialize a molecular diagnostic test for Philadelphia chromosome-positive chronic myelogenous leukemia, or Ph+CML.

The Xpert BCR-ABL test is based on Cepheid's GeneXpert system. It is CE marked and has been available for sale outside the US since 2006. The deal announced today would accelerate efforts to get clearance from the US Food and Drug Administration for commercial launch in the US of the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.